Myasthenia Gravis Treatments
Find Myasthenia Gravis Treatments
Medications for Myasthenia Gravis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Myasthenia Gravis.
Found 8 Approved Drugs for Myasthenia Gravis
Pyridostigmine
Brand Names
Mestinon, Pryidostigmine, Regonol
Pyridostigmine
Brand Names
Mestinon, Pryidostigmine, Regonol
Form: Injection, Tablet, Solution
Method of administration: Oral, Intravenous, Parenteral
FDA approval date: April 06, 1955
Classification: Cholinesterase Inhibitor
INDICATION: MESTINON is useful in the treatment of myasthenia gravis.
Efgartigimod
Brand Names
Vyvgart, VYVGART Hytrulo
Efgartigimod
Brand Names
Vyvgart, VYVGART Hytrulo
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: December 17, 2021
Classification: Endoglycosidase
VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). VYVGART is a neonatal Fc receptor blocker indicated for the treatment of adult patients with generalized myasthenia gravis (gMG). ( 1 )
Eculizumab
Brand Names
BKEMV, Epysqli, Soliris
Eculizumab
Brand Names
BKEMV, Epysqli, Soliris
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Ultomiris
Generic Name
Ravulizumab
Ultomiris
Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
ULTOMIRIS is indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA) ( 1 ). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
Rystiggo
Generic Name
Rozanolixizumab
Rystiggo
Generic Name
Rozanolixizumab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 26, 2023
Classification: Neonatal Fc Receptor Blocker
RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. ( 1 )
Showing 1-5 of 8
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances